Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral
MGL-3196-11
Phase 3 small_molecule active
Quick answer
Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral for Non-Alcoholic Steatohepatitis (NASH) is a Phase 3 program (small_molecule) at Madrigal Pharmaceuticals EU Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Madrigal Pharmaceuticals EU Limited
- Indication
- Non-Alcoholic Steatohepatitis (NASH)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active